Fenchem Opens SAM-e Plant in Europe

OSTRAVA VIT KOVICE, Czech RepublicFenchem is opening a SAM-e facility in the Czech Republic to supply Europe with its SAMe-way ingredient. Fenchem established it European head office in the Czech Republicin 2010 and continues to grow in the human and animal nutraceutical business in Europe.

Fenchem, Nanjing, China, said it created its SAM-e operation in Europe due to the growing demand locally and the safety concerns of China origin products, as the United States and the EU are its target markets. The company noted FDA found contaminants in vegetable proteins imported into the United States from China in 2007. In it new Czech production site, Fenchem said it established a professional management system from raw material purchasing, developing, manufacturing to quality testing, to control all production stages to ensure customers with ingredients of high quality and safety standards.

SAM-e is a natural compound found in every human cell and involved in more than 35 biochemical processes in the body. It is traditionally sold as a prescription medication in Europe, and however as dietary supplement in the United States in the treatment of many conditions including depression, liver disease and osteoarthritis etc. It is also used as supplement in dogs and cats to preserve and fortify liver function.

Fenchems SAMe-way SAM-e is available in two salt forms, Ademetionine 1,4-Butanedisulfonate and Ademetionine Disulfate Tosylate. In SAMe-way, the ratio of active ingredient (s,s) isomer is up to more than 70 percent, designed to ensure high bioavailability and cost savings.